Healthcare Industry News: VYTORIN
News Release - April 12, 2006
Schering-Plough Appoints Raymond Russo Vice President, Global Cholesterol MarketingKENILWORTH, N.J., April 12 (HSMN NewsFeed) -- Schering-Plough Corporation (NYSE: SGP ) today announced the promotion of Raymond Russo to vice president, Global Cholesterol Marketing. He reports to Sean McNicholas, senior vice president, Strategic Partnerships and U.S. Managed Markets. Most recently, Russo served as vice president, U.S. Cholesterol Marketing.
Since joining Schering-Plough in 1982 as a financial analyst, Russo has held a number of increasingly responsible positions within the company's finance, contracts and marketing organizations. In his most recent role, Russo was in charge of ZETIA® (ezetimibe) and VYTORIN® (ezetimibe/simvastatin) in the company's cholesterol joint venture in the U.S. and was instrumental in driving higher sales and market share of the franchise.
In his new position, Russo retains his previous duties and assumes responsibility for the cholesterol franchise for the rest of the world, excluding Japan. In addition to ZETIA and VYTORIN, Russo will be responsible for in-licensed cardiovascular products as well as those developed within Schering-Plough Research Institute.
Russo earned his M.B.A. in accounting and B.A. in economics at Rutgers University.
Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 32,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.